3-(Pyrrolidino-methyl)-1-methyl-piperidin | 95440-33-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(Pyrrolidino-methyl)-1-methyl-piperidin
• 英文别名: 1-methyl-3-pyrrolidin-1-ylmethyl-piperidine；1-methyl-3-pyrrolidinomethyl-piperidine；1-Methyl-3-pyrrolidinomethyl-piperidin；1-Methyl-3-(pyrrolidin-1-ylmethyl)piperidine
• CAS: 95440-33-8
• 化学式: C₁₁H₂₂N₂
• 分子量: 182.309
• InChiKey: FEJFAOFAZQWLNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 3-(Pyrrolidino-methyl)-1-methyl-piperidin
  参考文献：
  名称：

  Hypotensive Agents. Pyridinecarboxamides and Piperidinecarboxamides¹

  摘要：

  DOI：

  10.1021/ja01512a051

文献信息

• [EN] PROCESSES FOR THE PREPARATION OF ROXADUSTAT AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉS DESTINÉS À LA PRÉPARATION DE ROXADUSTATE ET SES INTERMÉDIAIRES
  申请人：TEVA PHARMACEUTICALS INT GMBH

  公开号：WO2021026307A1

  公开（公告）日：2021-02-11

  The present invention provides new procedure and intermediates for the preparation of Roxadustat (1) comprising: (A) reducing a compound of formula 3', 3" or a mixture thereof: (3'), (3") wherein Pg is H or a OH protecting group, Ri is alkyl, aryl, or arylalkyl; R2, R3, R4, and Rs each independently represents alkyl, arylalkyl or alkenyl, or R2 and R3 and/or R4 and Rs, taken together with the nitrogen atom to which they are bonded, each independently form a ring selected from: (I), wherein R6 is H or CI- 6 alkyl; R7 is Ci to C6 alkyl and X- is an anion selected from the group consisting of halide, O-SO4 -R7 wherein R7 is Ci to C6 alkyl, or O-SO2 -Rs wherein Rs is phenyl, tolyl, methyl or trifluoromethyl; to form a compound of formula (2') wherein Pg is H or an OH protecting group, Ri is alkyl, aryl, or arylalkyl; and removing the Ri group and where present removing the OH protecting group; or (B) reducing a compound of formula 4', a compound of formula 4" or a mixture thereof: (4'), (4") wherein Pg is H or an OH protecting group; Ri is H, alkyl, aryl, or arylalkyl; R2, R3, R4, and R5 each independently represents alkyl, aryl, arylalkyl or alkenyl; or R2 is Ci-4 alkyl and R3 is Ci-4 alkoxy; or R2 and R3 and/or R4 and R5, taken together with the nitrogen atom to which they are bonded, each independently form a group selected from: (I) wherein R6 is H or CI-6 alkyl; and where Ri is not H, removing the Ri group, and, where present removing the OH protecting group.

  本发明提供了制备罗沙度胺（1）的新程序和中间体，包括：（A）还原式3'、3"或其混合物的化合物：（3'）、（3"），其中Pg为H或OH保护基，Ri为烷基、芳基或芳基烷基；R2、R3、R4和Rs分别独立表示烷基、芳基烷基或烯基，或者R2和R3和/或R4和Rs与它们连接的氮原子一起，各自独立地形成从选定的环中选择的环：（I），其中R6为H或CI-6烷基；R7为Ci至C6烷基，X-为从卤素、O-SO4-R7（其中R7为Ci至C6烷基）或O-SO2-Rs（其中Rs为苯基、甲苯基、甲基或三氟甲基）中选择的阴离子；形成式（2'）的化合物，其中Pg为H或OH保护基，Ri为烷基、芳基或芳基烷基；并去除Ri基团和如有的话去除OH保护基；或（B）还原式4'、4"或其混合物的化合物：（4'）、（4"），其中Pg为H或OH保护基；Ri为H、烷基、芳基或芳基烷基；R2、R3、R4和R5各自独立表示烷基、芳基、芳基烷基或烯基；或R2为Ci-4烷基，R3为Ci-4烷氧基；或者R2和R3和/或R4和R5与它们连接的氮原子一起，各自独立地形成从选定的组中选择的组：（I），其中R6为H或CI-6烷基；并且如果Ri不是H，则去除Ri基团，并在有的情况下去除OH保护基。
• BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS
  申请人：Anacor Pharmaceuticals, Inc.

  公开号：EP3246034A1

  公开（公告）日：2017-11-22

  Compounds and methods of treating anti-inflammatory conditions are disclosed. The compounds are benzoxaboroles and in particular are 5-phenoxy-1-hydroxy-2,1-benzoxaboroles and 5-pyridin-2-yloxy-1-hydroxy-2,1-benzoxaboroles.

  本发明公开了治疗抗炎症状的化合物和方法。这些化合物是苯并氧硼烷，特别是 5-苯氧基-1-羟基-2,1-苯并氧硼烷和 5-吡啶-2-基氧基-1-羟基-2,1-苯并氧硼烷。
• Cyanoindoline derivatives as NIK inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US11186589B2

  公开（公告）日：2021-11-30

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及可用于哺乳动物治疗和/或预防的药物制剂，尤其涉及可用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病等疾病的NF-κB诱导激酶（NIK-又称MAP3K14）抑制剂。本发明还涉及包含此类化合物的药物组合物，以及使用此类化合物或药物组合物预防或治疗癌症、炎症性疾病、代谢紊乱（包括肥胖和糖尿病）和自身免疫性疾病等疾病。
• ARYLSULFONAMIDE WIRKSAM ALS SCHMERZMITTEL
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2240458B1

  公开（公告）日：2011-08-03
• UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS
  申请人：Technische Universität München

  公开号：EP3464260B1

  公开（公告）日：2021-10-27